Matches in Nanopublications for { ?s <http://www.w3.org/2000/01/rdf-schema#label> ?o ?g. }
- SENTENCE label "The average mass loads of PGE2 and 5-iPF2α-VI in a community were significantly increased (two-tailed p < 0.001) from the first month of COVID-19 pandemic to the second month; however, significantly decreased (two-tailed p < 0.001) in the third month." provenance.
- SENTENCE label "The average mass loads of PGE2 and 5-iPF2α-VI in a community were significantly increased (two-tailed p < 0.001) from the first month of COVID-19 pandemic to the second month; however, significantly decreased (two-tailed p < 0.001) in the third month." provenance.
- SENTENCE label "The average mass loads of PGE2 and 5-iPF2α-VI in a community were significantly increased (two-tailed p < 0.001) from the first month of COVID-19 pandemic to the second month; however, significantly decreased (two-tailed p < 0.001) in the third month." provenance.
- SENTENCE label "The average mass loads of PGE2 and 5-iPF2α-VI in a community were significantly increased (two-tailed p < 0.001) from the first month of COVID-19 pandemic to the second month; however, significantly decreased (two-tailed p < 0.001) in the third month." provenance.
- SENTENCE label "So far, remdesivir and dexamethasone have shown clinical effectiveness in severe COVID-19 in hospitalized patients." provenance.
- SENTENCE label "So far, remdesivir and dexamethasone have shown clinical effectiveness in severe COVID-19 in hospitalized patients." provenance.
- SENTENCE label "So far, remdesivir and dexamethasone have shown clinical effectiveness in severe COVID-19 in hospitalized patients." provenance.
- SENTENCE label "So far, remdesivir and dexamethasone have shown clinical effectiveness in severe COVID-19 in hospitalized patients." provenance.
- SENTENCE label "So far, remdesivir and dexamethasone have shown clinical effectiveness in severe COVID-19 in hospitalized patients." provenance.
- SENTENCE label "So far, remdesivir and dexamethasone have shown clinical effectiveness in severe COVID-19 in hospitalized patients." provenance.
- SENTENCE label "So far, remdesivir and dexamethasone have shown clinical effectiveness in severe COVID-19 in hospitalized patients." provenance.
- SENTENCE label "So far, remdesivir and dexamethasone have shown clinical effectiveness in severe COVID-19 in hospitalized patients." provenance.
- SENTENCE label "In the mechanically-ventilated COVID-19 population, treatment with dexamethasone showed significant protection against mortality (single study)." provenance.
- SENTENCE label "In the mechanically-ventilated COVID-19 population, treatment with dexamethasone showed significant protection against mortality (single study)." provenance.
- SENTENCE label "In the mechanically-ventilated COVID-19 population, treatment with dexamethasone showed significant protection against mortality (single study)." provenance.
- SENTENCE label "In the mechanically-ventilated COVID-19 population, treatment with dexamethasone showed significant protection against mortality (single study)." provenance.
- SENTENCE label "In the mechanically-ventilated COVID-19 population, treatment with dexamethasone showed significant protection against mortality (single study)." provenance.
- SENTENCE label "In the mechanically-ventilated COVID-19 population, treatment with dexamethasone showed significant protection against mortality (single study)." provenance.
- SENTENCE label "In the mechanically-ventilated COVID-19 population, treatment with dexamethasone showed significant protection against mortality (single study)." provenance.
- SENTENCE label "In the mechanically-ventilated COVID-19 population, treatment with dexamethasone showed significant protection against mortality (single study)." provenance.
- SENTENCE label "In the mechanically-ventilated COVID-19 population, treatment with dexamethasone showed significant protection against mortality (single study)." provenance.
- SENTENCE label "In the mechanically-ventilated COVID-19 population, treatment with dexamethasone showed significant protection against mortality (single study)." provenance.
- SENTENCE label "In the mechanically-ventilated COVID-19 population, treatment with dexamethasone showed significant protection against mortality (single study)." provenance.
- SENTENCE label "In the mechanically-ventilated COVID-19 population, treatment with dexamethasone showed significant protection against mortality (single study)." provenance.
- SENTENCE label "In the mechanically-ventilated COVID-19 population, treatment with dexamethasone showed significant protection against mortality (single study)." provenance.
- SENTENCE label "In the mechanically-ventilated COVID-19 population, treatment with dexamethasone showed significant protection against mortality (single study)." provenance.
- SENTENCE label "In the mechanically-ventilated COVID-19 population, treatment with dexamethasone showed significant protection against mortality (single study)." provenance.
- SENTENCE label "In the mechanically-ventilated COVID-19 population, treatment with dexamethasone showed significant protection against mortality (single study)." provenance.
- SENTENCE label "In the mechanically-ventilated COVID-19 population, treatment with dexamethasone showed significant protection against mortality (single study)." provenance.
- SENTENCE label "In the mechanically-ventilated COVID-19 population, treatment with dexamethasone showed significant protection against mortality (single study)." provenance.
- SENTENCE label "In the mechanically-ventilated COVID-19 population, treatment with dexamethasone showed significant protection against mortality (single study)." provenance.
- SENTENCE label "In the mechanically-ventilated COVID-19 population, treatment with dexamethasone showed significant protection against mortality (single study)." provenance.
- SENTENCE label "AA (arachidonic acid) is the precursor of both prostaglandin E2 (PGE2) and LXA4 suggesting that AA (arachidonic acid) is most suited for such preventive and therapeutic approach." provenance.
- SENTENCE label "AA (arachidonic acid) is the precursor of both prostaglandin E2 (PGE2) and LXA4 suggesting that AA (arachidonic acid) is most suited for such preventive and therapeutic approach." provenance.
- SENTENCE label "AA (arachidonic acid) is the precursor of both prostaglandin E2 (PGE2) and LXA4 suggesting that AA (arachidonic acid) is most suited for such preventive and therapeutic approach." provenance.
- SENTENCE label "AA (arachidonic acid) is the precursor of both prostaglandin E2 (PGE2) and LXA4 suggesting that AA (arachidonic acid) is most suited for such preventive and therapeutic approach." provenance.
- SENTENCE label "AA (arachidonic acid) is the precursor of both prostaglandin E2 (PGE2) and LXA4 suggesting that AA (arachidonic acid) is most suited for such preventive and therapeutic approach." provenance.
- SENTENCE label "AA (arachidonic acid) is the precursor of both prostaglandin E2 (PGE2) and LXA4 suggesting that AA (arachidonic acid) is most suited for such preventive and therapeutic approach." provenance.
- SENTENCE label "AA (arachidonic acid) is the precursor of both prostaglandin E2 (PGE2) and LXA4 suggesting that AA (arachidonic acid) is most suited for such preventive and therapeutic approach." provenance.
- SENTENCE label "AA (arachidonic acid) is the precursor of both prostaglandin E2 (PGE2) and LXA4 suggesting that AA (arachidonic acid) is most suited for such preventive and therapeutic approach." provenance.
- SENTENCE label "AA (arachidonic acid) is the precursor of both prostaglandin E2 (PGE2) and LXA4 suggesting that AA (arachidonic acid) is most suited for such preventive and therapeutic approach." provenance.
- SENTENCE label "AA (arachidonic acid) is the precursor of both prostaglandin E2 (PGE2) and LXA4 suggesting that AA (arachidonic acid) is most suited for such preventive and therapeutic approach." provenance.
- SENTENCE label "AA (arachidonic acid) is the precursor of both prostaglandin E2 (PGE2) and LXA4 suggesting that AA (arachidonic acid) is most suited for such preventive and therapeutic approach." provenance.
- SENTENCE label "AA (arachidonic acid) is the precursor of both prostaglandin E2 (PGE2) and LXA4 suggesting that AA (arachidonic acid) is most suited for such preventive and therapeutic approach." provenance.
- SENTENCE label "AA (arachidonic acid) is the precursor of both prostaglandin E2 (PGE2) and LXA4 suggesting that AA (arachidonic acid) is most suited for such preventive and therapeutic approach." provenance.
- SENTENCE label "AA (arachidonic acid) is the precursor of both prostaglandin E2 (PGE2) and LXA4 suggesting that AA (arachidonic acid) is most suited for such preventive and therapeutic approach." provenance.
- SENTENCE label "AA (arachidonic acid) is the precursor of both prostaglandin E2 (PGE2) and LXA4 suggesting that AA (arachidonic acid) is most suited for such preventive and therapeutic approach." provenance.
- SENTENCE label "AA (arachidonic acid) is the precursor of both prostaglandin E2 (PGE2) and LXA4 suggesting that AA (arachidonic acid) is most suited for such preventive and therapeutic approach." provenance.
- SENTENCE label "AA (arachidonic acid) is the precursor of both prostaglandin E2 (PGE2) and LXA4 suggesting that AA (arachidonic acid) is most suited for such preventive and therapeutic approach." provenance.
- SENTENCE label "AA (arachidonic acid) is the precursor of both prostaglandin E2 (PGE2) and LXA4 suggesting that AA (arachidonic acid) is most suited for such preventive and therapeutic approach." provenance.
- SENTENCE label "AA (arachidonic acid) is the precursor of both prostaglandin E2 (PGE2) and LXA4 suggesting that AA (arachidonic acid) is most suited for such preventive and therapeutic approach." provenance.
- SENTENCE label "AA (arachidonic acid) is the precursor of both prostaglandin E2 (PGE2) and LXA4 suggesting that AA (arachidonic acid) is most suited for such preventive and therapeutic approach." provenance.
- SENTENCE label "AA (arachidonic acid) is the precursor of both prostaglandin E2 (PGE2) and LXA4 suggesting that AA (arachidonic acid) is most suited for such preventive and therapeutic approach." provenance.
- SENTENCE label "AA (arachidonic acid) is the precursor of both prostaglandin E2 (PGE2) and LXA4 suggesting that AA (arachidonic acid) is most suited for such preventive and therapeutic approach." provenance.
- SENTENCE label "AA (arachidonic acid) is the precursor of both prostaglandin E2 (PGE2) and LXA4 suggesting that AA (arachidonic acid) is most suited for such preventive and therapeutic approach." provenance.
- SENTENCE label "AA (arachidonic acid) is the precursor of both prostaglandin E2 (PGE2) and LXA4 suggesting that AA (arachidonic acid) is most suited for such preventive and therapeutic approach." provenance.
- SENTENCE label "Additionally, using higher doses of dexamethasone for prolonged periods of time can lead to severe side effects and some patients may develop corticosteroid resistance leading to treatment failure." provenance.
- SENTENCE label "Additionally, using higher doses of dexamethasone for prolonged periods of time can lead to severe side effects and some patients may develop corticosteroid resistance leading to treatment failure." provenance.
- SENTENCE label "Additionally, using higher doses of dexamethasone for prolonged periods of time can lead to severe side effects and some patients may develop corticosteroid resistance leading to treatment failure." provenance.
- SENTENCE label "Additionally, using higher doses of dexamethasone for prolonged periods of time can lead to severe side effects and some patients may develop corticosteroid resistance leading to treatment failure." provenance.
- SENTENCE label "Additionally, using higher doses of dexamethasone for prolonged periods of time can lead to severe side effects and some patients may develop corticosteroid resistance leading to treatment failure." provenance.
- SENTENCE label "Additionally, using higher doses of dexamethasone for prolonged periods of time can lead to severe side effects and some patients may develop corticosteroid resistance leading to treatment failure." provenance.
- SENTENCE label "Additionally, using higher doses of dexamethasone for prolonged periods of time can lead to severe side effects and some patients may develop corticosteroid resistance leading to treatment failure." provenance.
- SENTENCE label "Additionally, using higher doses of dexamethasone for prolonged periods of time can lead to severe side effects and some patients may develop corticosteroid resistance leading to treatment failure." provenance.
- SENTENCE label "Additionally, using higher doses of dexamethasone for prolonged periods of time can lead to severe side effects and some patients may develop corticosteroid resistance leading to treatment failure." provenance.
- SENTENCE label "Additionally, using higher doses of dexamethasone for prolonged periods of time can lead to severe side effects and some patients may develop corticosteroid resistance leading to treatment failure." provenance.
- SENTENCE label "Additionally, using higher doses of dexamethasone for prolonged periods of time can lead to severe side effects and some patients may develop corticosteroid resistance leading to treatment failure." provenance.
- SENTENCE label "Additionally, using higher doses of dexamethasone for prolonged periods of time can lead to severe side effects and some patients may develop corticosteroid resistance leading to treatment failure." provenance.
- SENTENCE label "Additionally, using higher doses of dexamethasone for prolonged periods of time can lead to severe side effects and some patients may develop corticosteroid resistance leading to treatment failure." provenance.
- SENTENCE label "Additionally, using higher doses of dexamethasone for prolonged periods of time can lead to severe side effects and some patients may develop corticosteroid resistance leading to treatment failure." provenance.
- SENTENCE label "Additionally, using higher doses of dexamethasone for prolonged periods of time can lead to severe side effects and some patients may develop corticosteroid resistance leading to treatment failure." provenance.
- SENTENCE label "Additionally, using higher doses of dexamethasone for prolonged periods of time can lead to severe side effects and some patients may develop corticosteroid resistance leading to treatment failure." provenance.
- SENTENCE label "Additionally, using higher doses of dexamethasone for prolonged periods of time can lead to severe side effects and some patients may develop corticosteroid resistance leading to treatment failure." provenance.
- SENTENCE label "Additionally, using higher doses of dexamethasone for prolonged periods of time can lead to severe side effects and some patients may develop corticosteroid resistance leading to treatment failure." provenance.
- SENTENCE label "Additionally, using higher doses of dexamethasone for prolonged periods of time can lead to severe side effects and some patients may develop corticosteroid resistance leading to treatment failure." provenance.
- SENTENCE label "Additionally, using higher doses of dexamethasone for prolonged periods of time can lead to severe side effects and some patients may develop corticosteroid resistance leading to treatment failure." provenance.
- SENTENCE label "Additionally, using higher doses of dexamethasone for prolonged periods of time can lead to severe side effects and some patients may develop corticosteroid resistance leading to treatment failure." provenance.
- SENTENCE label "Additionally, using higher doses of dexamethasone for prolonged periods of time can lead to severe side effects and some patients may develop corticosteroid resistance leading to treatment failure." provenance.
- SENTENCE label "Recent trials with dexamethasone and hydrocortisone have demonstrated benefit in patients with coronavirus disease 2019 (COVID)-19)." provenance.
- SENTENCE label "Recent trials with dexamethasone and hydrocortisone have demonstrated benefit in patients with coronavirus disease 2019 (COVID)-19)." provenance.
- SENTENCE label "Recent trials with dexamethasone and hydrocortisone have demonstrated benefit in patients with coronavirus disease 2019 (COVID)-19)." provenance.
- SENTENCE label "Recent trials with dexamethasone and hydrocortisone have demonstrated benefit in patients with coronavirus disease 2019 (COVID)-19)." provenance.
- SENTENCE label "Recent trials with dexamethasone and hydrocortisone have demonstrated benefit in patients with coronavirus disease 2019 (COVID)-19)." provenance.
- SENTENCE label "Recent trials with dexamethasone and hydrocortisone have demonstrated benefit in patients with coronavirus disease 2019 (COVID)-19)." provenance.
- SENTENCE label "early dexamethasone group showed a significantly lower rate of severe COVID-19 compared to the control group (75.9% vs 40.0%, P-value=0.012)." provenance.
- SENTENCE label "early dexamethasone group showed a significantly lower rate of severe COVID-19 compared to the control group (75.9% vs 40.0%, P-value=0.012)." provenance.
- SENTENCE label "early dexamethasone group showed a significantly lower rate of severe COVID-19 compared to the control group (75.9% vs 40.0%, P-value=0.012)." provenance.
- SENTENCE label "early dexamethasone group showed a significantly lower rate of severe COVID-19 compared to the control group (75.9% vs 40.0%, P-value=0.012)." provenance.
- SENTENCE label "early dexamethasone group showed a significantly lower rate of severe COVID-19 compared to the control group (75.9% vs 40.0%, P-value=0.012)." provenance.
- SENTENCE label "early dexamethasone group showed a significantly lower rate of severe COVID-19 compared to the control group (75.9% vs 40.0%, P-value=0.012)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021-0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021-0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021-0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021-0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021-0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021-0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021-0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021-0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021-0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021-0.36]; P < 0.001)." provenance.